Dr. Seibyl co‐founded IND in 2001 and has provided scientific leadership since IND’s founding. Prior to IND, Dr. Seibyl was Chief, Section of Nuclear Medicine and Associate Professor of Diagnostic Radiology and Psychiatry, Yale University School of Medicine. He completed Fellowship training in both Psychiatry and Nuclear Medicine at Yale and over the course of the last 30 years has focused on the development of scintigraphic imaging biomarkers using SPECT and PET to address clinical research and clinical practice questions in neurodegenerative disorders, especially PD and Alzheimer’s. In the latter, he helped develop and validate the visual read method for the amyloid PET agent 18‐F Florbetaben, and more recently the latest generation of tau PET agents. Dr. Seibyl has won numerous grants and contracts, serves on international panels as a grant reviewer, advisor, and consultant and has over 250 publications. He is the Imaging Core PI for the Parkinsons Progression Marker Initiative (PPMI) and is a unique advocate for the Parkinson’s patient community, ironically having developed PD seven years ago.